Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)
Source: SeekingAlpha
2026-03-30 09:17:55 ET
Since my article , "My Top 5 Biotech Stocks Big Pharma Could Buy Next," Kamada shares ( KMDA ) have risen 22.4%, outperforming the so-called "bellwether" for the biotech investors, the iShares Biotechnology ETF [6.5% return] ( IBB ), as well as the S&P 500 [-3.9%] ( SPY )....
Read the full article on Seeking Alpha
For further details see:
Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)
Grifols S.A.
NASDAQ: GRFS
GRFS Trading
1.22% G/L:
$7.652 Last:
177,069 Volume:
$7.64 Open:
GRFS Latest News
GRFS Stock Data
$6,538,647,175
559,676,571
N/A
69
N/A
Pharmaceuticals
Healthcare
ES
Sant Cugat del Valles
